Skip to content

Adis in touch

A blog from Adis, a leading global provider of drug information.

Recent Posts

  • Planning and strategizing in the face of evolving regulatory guidelines: Report from the DIA Pharmacovigilance and Risk Management Strategies Conference (PVRMS19)
  • Researchers investigate how vial sizes can be optimized to reduce pharmaceutical wastage
  • Pharmacovigilance in the Middle East: Adis PV attends the regional ISoP meeting
  • The World Drug Safety Congress in Amsterdam addresses key challenges
  • Avatrombopag (Doptelet®): First Global Approval – Reducing the bleeding risks of invasive procedures in patients with Chronic Liver Disease

Recent Comments

Dr Paul Tappenden as… on Call for Papers: Themed Issue…
Dupilumab (Dupixent®… on Dupilumab (Dupixent®): First G…
Durvalumab (IMFENZI®… on Durvalumab (IMFINZI®): Follow…
Dupilumab (Dupixent®… on Dupilumab (Dupixent®): First G…
Baricitinib (Olumian… on Baricitinib (Olumiant™): First…

Archives

  • February 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • April 2016
  • October 2015
  • July 2015
  • June 2015
  • February 2015
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • May 2014
  • March 2014
  • January 2014
  • October 2013
  • July 2013
  • January 2012

Categories

  • Adis (83)
  • Adis Journals (91)
  • Adis Pharmacovigilance (24)
  • AdisInsight (92)
  • Uncategorized (2)

Tag: England

Dupilumab (Dupixent®): NICE Publishes Positive Final Appraisal Determination

Dupilumab (Dupixent®): NICE Publishes Positive Final Appraisal Determination

Between March 2017 and January 2018 Dupilumab was approved in four major global regions: the US[1], the EU[2], Canada[3], and Japan.[4] Continue reading “Dupilumab (Dupixent®): NICE Publishes Positive Final Appraisal Determination” →

By Wendy McNeelyin Adis, Adis Journals, AdisInsightJuly 4, 2018116 WordsLeave a comment
Powered by WordPress.com.